Drug Development Strategy Archives - Clin Pharm Development Solutions

The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval

Clinical Pharmacology, Drug Development Strategy, Regulatory / Aniruddha

Executive Summary For a long time, the pharmaceutical industry viewed Clinical Pharmacology models as helpful supporting characters. They were tools used to guide a trial design or help justify a specific dose. As we move through 2026, a fundamental shift has taken place. The FDA and EMA have moved from Model Informed to Model Integrated […]

The MIE Shift: When the Model Becomes the Primary Evidence for FDA Approval Read More »

Beyond Biosimilarity: The 2026 Strategic Blueprint for Day 1 Interchangeability

Drug Development Strategy / Aniruddha

Beyond Biosimilarity: The 2026 Strategic Blueprint for Day 1 Interchangeability Executive Summary For over a decade, the Interchangeable designation was the most expensive badge of honor in the biosimilar industry, typically requiring a multi-million dollar clinical switching trial. As of early 2026, the regulatory wall has collapsed. Following the FDA’s pivotal June 2024 guidance and

Biosimilar Development in 2025: From Comparative Trials to Analytical Confidence

Drug Development Strategy / Aniruddha

A joint evolution in FDA and EMA guidance signals a paradigm shift toward efficiency, science, and patient access. 1. The Changing Landscape For nearly two decades, biosimilar development followed a familiar path: prove similarity through large, comparative efficacy studies against the reference product. These studies—costly, time-consuming, and often redundant—became the accepted norm. In 2025, both

Rethinking “Me-Too” Drugs: Leveraging Validated Pathways for Faster and Smarter Drug Development

Drug Development Strategy / Aniruddha

The CLUE framework for “next-in-class” and “me better” drugs. Introduction The term “me-too” drug has historically been used pejoratively to describe follow-on compounds perceived as redundant or commercially motivated imitations of first-in-class agents. Yet this view overlooks a critical reality of modern drug development: once a pathway or target is clinically validated, subsequent entrants can

Rethinking “Me-Too” Drugs: Leveraging Validated Pathways for Faster and Smarter Drug Development Read More »